NFE2L3

Across TCGA pan-cancer cohorts, NFE2L3 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NFE2L3 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NFE2L3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NFE2L3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and COAD are the cancer types where NFE2L3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.033	0.777	<.001	24	view →
UCEC	DFS	Median	II,III,IV	1.000	0.439	.019	10	view →
COAD	DFS	Median	All	0.317	0.694	.018	6	view →
LUAD	DFS	Median	IV	0.333	0.671	.048	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NFE2L3–LIHC (OS)

Open the LIHC breakdown →